Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID6235]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 March 2026
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 6 August 2026